Chemomab Therapeutics Ltd. — Director's Dealing 2021

Mar 26, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Chemomab Therapeutics Ltd. (CMMB)
CIK: 0001534248
Period of Report: 2021-03-16

Reporting Person: OrbiMed Israel GP Ltd. (10% Owner)
Reporting Person: OrbiMed Israel BioFund GP Limited Partnership (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
American Depository Shares	2290004	Indirect

Footnotes

F1: Received in exchange for ordinary shares of Chemomab Ltd. in connection with the merger of Chemomab Ltd. into a wholly-owned subsidiary of the Issuer in accordance with the terms of an Agreement and Plan of Merger, dated as of December 14, 2020. Each American Depository Share ("ADS") represents twenty (20) ordinary shares of the Issuer.

F2: These securities of the Issuer are held of record by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel GP") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power with respect to the securities held directly by OIP noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Israel GP exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP.

F3: This report is being jointly filed by OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.